Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Authors:
- Jon B ToledoJTJon B Toledo
- Michael W WeinerMWMichael W Weiner
- David A WolkDWDavid A Wolk
- Xiao DaXDXiao Da
- Kewei ChenKCKewei Chen
- Steven E ArnoldSASteven E Arnold
- William JagustWJWilliam Jagust
- Clifford JackCJClifford Jack
- Eric M ReimanEREric M Reiman
- Christos DavatzikosCDChristos Davatzikos
- Leslie M ShawLSLeslie M Shaw
- John Q TrojanowskiJTJohn Q Trojanowski
Open Access
- 6 March 2014
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 2 (1) , 26
Abstract
Based on previous studies, a preclinical classification for Alzheimer’s disease (AD) has been proposed. However, 1) specificity of the different neuronal injury (NI) biomarkers has not been studied, 2) subjects with subtle cognitive impairment but normal NI biomarkers (SCINIB) have not been included in the analyses and 3) progression to mild cognitive impairment (MCI) or dementia of the AD type (DAT), referred to here as MCI/DAT, varies between studies. Therefore, we analyzed data from 486 cognitively normal (CN) and 327 DAT subjects in the AD Neuroimaging Initiative (ADNI)-1/GO/2 cohorts. In the ADNI-1 cohort (median follow-up of 6 years), 6.3% and 17.0% of the CN subjects developed MCI/DAT after 3 and 5 years follow-up, respectively. NI biomarker cutoffs [structural magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (FDG-PET) and cerebrospinal fluid (CSF) tau] were established in DAT patients and memory composite scores were calculated in CN subjects in a cross-sectional sample (n = 160). In the complete longitudinally followed CN ADNI cohort (n = 326, median follow-up of 2 years), CSF and MRI values predicted an increased conversion to MCI/DAT. Different NI biomarkers showed important disagreements for classifying subjects as abnormal NI [kappa = (−0.05)-(0.33)] and into AD preclinical groups. SCINIB subjects (5.0%) were more prevalent than AD preclinical stage 3 subjects (3.4%) and showed a trend for increased progression to MCI/DAT. Different NI biomarkers lead to different classifications of ADNI subjects, while structural MRI and CSF tau measures showed the strongest predictive value for progression to MCI/DAT. The newly defined SCINIB category of ADNI subjects is more prevalent than AD preclinical stage individuals.Keywords
This publication has 41 references indexed in Scilit:
- TDP-43 Pathology, Cognitive Decline, and Dementia in Old AgeJAMA Neurology, 2013
- Preclinical AD predicts decline in memory and executive functions in subjective complaintsNeurology, 2013
- Preclinical Alzheimer's disease and its outcome: a longitudinal cohort studyThe Lancet Neurology, 2013
- Early Indications of Future Cognitive Decline: Stable versus Declining ControlsPLOS ONE, 2013
- Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating CentreBrain, 2013
- The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inceptionAlzheimer's & Dementia, 2013
- Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNIActa Neuropathologica, 2013
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort studyThe Lancet Neurology, 2013
- White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degenerationJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Brain β-amyloid load approaches a plateauNeurology, 2013